+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism



Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism



Clinical Endocrinology 35(2): 145-150



The purpose of this investigation was to evaluate the effectiveness of short-term administration of recombinant biosynthetic IGF-I on patients with an hereditary inability to generate this hormone. Ten patients with Laron type dwarfism (LTD) (4 males, six females) aged 3 1/2 to 37 3/4 years were submitted to seven daily s.c. injections of recombinant IGF-I in doses of 120 or 150 micrograms/kg/day. Blood samples were drawn before, after three and seven injections, and one week after stopping the trial. The main biochemical and hormonal changes registered were (mean +/- SD): a marked rise in serum type III procollagen (PIIINP) from 4.2 +/- 0.9 to 7.3 +/- 2 micrograms/l (P less than 0.0003) and decrease in the following blood components: plasma hGH from 32.51 +/- 43.77 to 4.02 +/- 2.48 mU/l (P less than 0.001), serum cholesterol from 5.9 +/- 1 to 5.7 +/- 0.8 mmol/l (P less than 0.04), serum SGOT from 28.9 +/- 11.6 to 15.5 +/- 7.6 U/l (P less than 0.01) and serum LDH from 286 +/- 88 to 222 +/- 37 U/l (P less than 0.0005). The response of plasma insulin was variable, decreasing in seven of ten and increasing in three. Some of these effects were transitory, and were found after 3 days therapy but afterwards decreased (insulin, cholesterol and liver tests), others persisted throughout the whole treatment period (hGH, PIINP). IGF-I mimics the biochemical and hormonal changes described after administration of hGH. The administration of IGF-I in patients with Laron type dwarfism is devoid of side-effects and warrants assessment in long-term studies.

(PDF emailed within 0-6 h: $19.90)

Accession: 039391735

Download citation: RISBibTeXText

PMID: 1934530

DOI: 10.1111/j.1365-2265.1991.tb03513.x


Related references

Igf binding protein 3 in patients with laron type dwarfism effect of exogenous rigf 1. Clinical Endocrinology 36(3): 301-304, 1992

Effect of acute administration of insulin like growth factor in patients with laron type dwarfism. Lancet 2(8621): 1170-1172, 1988

Laron-type dwarfism: heterogeneity of the biochemical abnormality in 3 children and their parents. Comptes Rendus de l'Academie des Sciences. Serie Iii, Sciences de la Vie 311(9): 315-319, 1990

Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs. Developmental Pharmacology and Therapeutics 15(3-4): 196-199, 1990

Pseudohypophyseal laron type dwarfism in 4 patients. Helvetica Paediatrica Acta 40(2-3): 216, 1985

Interest of IGF-1 and IGF-BPs measurements in patients with Laron-type dwarfism. Laron, Z, Parks, J S Pediatric and Adolescent Endocrinology; Lessons from Laron Syndrome (LS) 1966-1992: A model of GH and IGF-1 action and interaction: 181-184, 1993

Syndrome of familial dwarfism and high plasma immuno reactive growth hormone laron type dwarfism. Paediatrician 6(2): 106-117, 1977

Carbohydrate metabolism in the syndrome of familial dwarfism and high plasma immuno reactive growth hormone laron type dwarfism. Podolsky, S. Viswanathan (ed.). Secondary Diabetes: The Spectrum Of The Diabetic Syndromes. Xxi 602p. Raven Press: New York, N.y., Usa. Illus. Maps. P363-372, 1980

Growth hormone (hGH) secretion and turnover in three patients with Laron-type dwarfism. Israel Journal of Medical Sciences 24(2): 75-79, 1988

Prolactin response to intravenous igf i and trh stimulation in laron type dwarfism ltd patients and controls. Hormone Research 35(SUPPL 2): 38, 1991

Elimination of biosynthetic igf i injected to patients with laron type dwarfism ltd and normal subjects. Hormone Research 31(SUPPL 1): 15, 1989

Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I. Hormone Research 37(4-5): 160-164, 1992

Defective human growth hormone receptors in the liver of 2 patients with laron type dwarfism. Pediatric Research 16(10): 901, 1982

Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Israel Journal of Medical Sciences 20(1): 8-11, 1984

Effect of insulin-like growth factor I on the thyroid axis in patients with Laron-type dwarfism and healthy subjects. Acta Endocrinologica 127(6): 515-519, 1992